



EOS imaging Launches EOS 3D Service, a 3D Modeling offering for Customers Worldwide

Montreal-based on line modeling service to provide personalized 3D data from EOS Stereo-Radiographic patient images

Paris, May 12, 2015 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced a new on line service offering that allows hospitals to outsource 3D modelling from EOS stereo-radiographic images. The 3D models will be generated at EOS' Canadian subsidiary in Montreal. These capabilities will be available to healthcare professionals with access to EOS images worldwide.

The 3D models and associated, automatically computed clinical data will be available for spine, hip and knee for aid in therapeutic decision, surgery planning and control. EOS 3D Service will also provide 3D modeling of the ribcage for research purposes as well as for the design of scoliosis braces.

EOS has already begun to offer this new service and a first agreement has been signed with the Setting Scoliosis Straight Foundation (SSSF), a not-for-profit foundation that supports the Harms Study Group in understanding and developing treatments of spinal deformities in children and adolescents. The Harms Study Group (HSG), formed in 1995, is a collaborative cohort of worldwide distinguished surgeons who perform comprehensive, multi-center research studies and share the results to advance the techniques of spinal deformity correction. EOS 3D Service to SSSF allows the Harms Study Group surgeons access to 3D data for their patients undergoing scoliosis surgery.

"EOS' modeling capabilities fit seamlessly into our strategic plan to research and identify new spinal deformity treatment techniques and we couldn't be more pleased to partner with the Company as the first users of the EOS 3D Service" said Michelle Marks, Executive Director of the SSSF.

Marie Meynadier, CEO of EOS imaging, said, "EOS 3D Service affords surgeons and bracing professionals currently without direct access to our sterEOS workstation to benefit from the powerhouse of our patient 3D models and data. We are happy to extend this service to all of our customers and to their referrals, adding further value to the suite of software and tools based on the EOS platform."

The EOS® system provides full-body stereo-radiographic images of patients in functional positions, in both 2D and 3D, as well as related software solutions. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Achievable) by bringing pediatric spine follow up exams at a dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS[®], the first full body, low dose 2D/3D imaging system, please visits <u>http://www.eos-imaging.com/</u>.

EOS imaging has been chosen to be included in the new EnterNext[©] PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris ISIN: FR0011191766 – Ticker: EOSI



Next press release: EFORT Congress presence, late May 2015.





About EOS imaging:

EOS imaging designs, develops, and markets EOS[®], an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

Contacts:

Anne Renevot CFO Ph: +33 (0)1 55 25 61 24 investors@eos-imaging.com

NewCap

Financial communication and investor relations Antoine Denry/ Pierre Laurent Ph: +33 (0)1 44 71 94 91 eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen Ph: 646-536-7002 callen@theruthgroup.com